Abstract: A ring voltage control oscillator includes: a conversion unit (100), cascaded multistage delay units (200) and cascaded multistage isolation buffer units (300). The conversion unit (100) receives a voltage signal controlled by the external, converts the voltage signal into a current signal and respectively transmits the current signal to a plurality of delay units (200) and a plurality of isolation buffer units (300).

Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.

Abstract: The invention relates to methods for treating chronic liver disease, in particular nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), with neutrophil elastase inhibitors. The invention further relates to pharmaceutical compositions comprising neutrophil elastase inhibitors.

Abstract: The present invention provides methods for increasing LDL particle size.

Abstract: A ring voltage control oscillator includes: a conversion unit (100), cascaded multistage delay units (200) and cascaded multistage isolation buffer units (300). The conversion unit (100) receives a voltage signal controlled by the external, converts the voltage signal into a current signal and respectively transmits the current signal to a plurality of delay units (200) and a plurality of isolation buffer units (300).

Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.

Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.

Abstract: Technologies for control and status register (CSR) access include a computing device that starts a firmware initialization phase. The firmware accesses a CSR at an abstract CSR address. The computing device determines whether an upper part of the CSR address matches a cached upper part of a previously accessed CSR address. If the upper parts do not match, the computing device converts the CSR address into a physical address and caches the upper part of the CSR address and the upper part of the physical address. If the upper parts match, the computing device combines a cached upper part of a previously accessed physical address with an offset of the CSR address. The upper part may include 20 bits and the lower part may include 12 bits. The physical address may be a PCIe address of the CSR added with an MMCFG base address. Other embodiments are described and claimed.

Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.

Abstract: A delay locked loop detection system (10), the system can be used for detecting the working state of a delay locked loop (400) and comprises: a signal generator (300), which is used for generating a reference clock and providing the reference clock to the delay locked loop (400); and a testing instrument (500), which is used for acquiring the clock signals output from the delay locked loop (400) and measuring whether the time delays thereof are consistent with expectations; the detection system (10) further comprises at least one of the following circuits: a pre-receiving circuit (100), which is used for receiving the reference clock from the signal generator (300) and amplifying and shaping the reference clock and then providing the reference clock to the delay locked loop (400); and a multiphase multiplexing circuit (200), which is used for receiving the clock signals output from the delay locked loop (400) and synthesizing and then providing a plurality of clock signals with different delay to the testing

Abstract: Embodiments may include a composition for oral drug delivery. The composition may include a physiologically active substance, a carrier compound, a mucoadhesive compound, and a permeation enhancer. The physiologically active substance may be transported across the stomach. The physiologically active substance may be stable and not degrade in the harsh gastric acid environment. To help protect the physiologically active substance, the physiologically active substance is mixed with the carrier. The carrier may be a liquid insoluble in the gastric acid of the stomach. The physiologically active substance may be soluble in the carrier. The mucoadhesive compound may be used to promote adsorption of the physiologically active substance to the lining of the stomach. The permeation enhancer may facilitate the transport of the physiologically active substance across the wall of the stomach.

Abstract: A signal amplification circuit comprises a low pass filter circuit (100). The low pass filter circuit (100) comprises two input ends and two output ends and further comprises two capacitors (C1, C2) having opposite polarities respectively connected between two output ends. A buffer circuit (200) comprises two input ends, a first operational amplifier (A1) and a second operational amplifier (A2), two output ends and a plurality of switches. A switched capacitor integrated circuit (300) comprises two input ends, a third operational amplifier (A3), a plurality of capacitor modules, a plurality of chopper modulators and two output ends. A signal switch (S) is used to control the on and off states of voltage signal before amplification.

Abstract: A sensor control circuit comprises a sensor (201), a filtering circuit (202), a buffering circuit (203), and an amplifying circuit (204). An output end of the sensor (201) is connected to an input end of the filtering circuit (202), an output end of the filtering circuit (202) is connected to an input end of the buffering circuit (203), and an output end of the buffering circuit (203) is connected to an input end of the amplifying circuit (204). Because the buffering circuit (203) is disposed between the filtering circuit (202) and the amplifying circuit (204), the sensor circuit has an advantage of full sampling. Further provided is an electronic apparatus using the sensor control circuit.

Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.

Abstract: An accelerator comprises: an accelerometer (100), configured to detect an acceleration of a motion of a carrier and output a corresponding electrical signal; a sampling and low-pass filter (200), coupled to the accelerometer (100), and configured to sample the electrical signal regularly and filter a noise from the electrical signal; an amplifier (300), configured to amplify the electrical signal after filtering the noise; an analog-to-digital converter (400), configured to convert the amplified electrical signal into a digital signal; a function control module (500), configured to process the digital signal and output a control signal to control the analog-to-digital converter (400), the amplifier (300), and the sampling and low-pass filter (200); and an oscillator module (600), configured to output, according to the control signal, a sampling signal to the sampling and low-pass filter (200), so as to control the sampling and low-pass filter (200) to sample the electrical signal regularly.

Abstract: A signal amplification circuit comprises a low pass filter circuit (100). The low pass filter circuit (100) comprises two input ends and two output ends and further comprises two capacitors (C1, C2) having opposite polarities respectively connected between two output ends. A buffer circuit (200) comprises two input ends, a first operational amplifier (A1) and a second operational amplifier (A2), two output ends and a plurality of switches. A switched capacitor integrated circuit (300) comprises two input ends, a third operational amplifier (A3), a plurality of capacitor modules, a plurality of chopper modulators and two output ends. A signal switch (S) is used to control the on and off states of voltage signal before amplification.

Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.

Abstract: Technologies for control and status register (CSR) access include a computing device that starts a firmware initialization phase. The firmware accesses a CSR at an abstract CSR address. The computing device determines whether an upper part of the CSR address matches a cached upper part of a previously accessed CSR address. If the upper parts do not match, the computing device converts the CSR address into a physical address and caches the upper part of the CSR address and the upper part of the physical address. If the upper parts match, the computing device combines a cached upper part of a previously accessed physical address with an offset of the CSR address. The upper part may include 20 bits and the lower part may include 12 bits. The physical address may be a PCIe address of the CSR added with an MMCFG base address. Other embodiments are described and claimed.

Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.

Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.